Journal of the American College of Radiology
Volume 6, Issue 2 , Pages 85-95 , February 2009

ACR Appropriateness Criteria® on Nonsurgical Treatment for Non–Small-Cell Lung Cancer: Poor Performance Status or Palliative Intent

  • Kenneth E. Rosenzweig, MD

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, New York
    • Corresponding Author InformationCorresponding author and reprints: Kenneth E. Rosenzweig, MD, Memorial Sloan-Kettering Cancer Center, Department of Radiation Oncology, 1275 York Avenue, Box 22, New York, NY 10065-6007
    • ,
  • Benjamin Movsas, MD

      Affiliations

    • Henry Ford Health System, Detroit, Michigan
    • ,
  • Jeff Bradley, MD

      Affiliations

    • Alvin J. Siteman Cancer Center, St Louis, Missouri
    • ,
  • Richard M. Gewanter, MD

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, Rockville Centre, New York
    • ,
  • Ramesh S. Gopal, MD

      Affiliations

    • University of Texas, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Ritsuko U. Komaki, MD

      Affiliations

    • University of Texas, M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Feng-Ming Kong, MD, PhD, MPH

      Affiliations

    • VA Health Center, Ann Arbor, Michigan
    • ,
  • Hoon Ku Lee, MD

      Affiliations

    • Regional Imaging & Therapeutic Radiology Services, PC, Staten Island, New York
    • ,
  • Richard H. Feins, MD

      Affiliations

    • University of North Carolina–Chapel Hill, Chapel Hill, North Carolina
    • ,
  • Corey J. Langer, MD

      Affiliations

    • Fox Chase Cancer Center, Philadelphia, Pennsylvania

References 

  1. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin. 1993;43:7–26
  2. Perez CA, Stanley K, Grundy G, et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: report by the Radiation Therapy Oncology Group. Cancer. 1982;50:1091–1099
  3. Haffty BG, Goldberg NB, Gerstley J, Fischer DB, Peschel RE. Results of radical radiation therapy in clinical stage I, technically operable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1988;15:69–73
  4. Hayakawa K, Mitsuhashi N, Nobuaki N, et al. Radiation therapy for stage I-III epidermoid carcinoma of the lung. Lung Cancer. 1992;8:213–223
  5. Hayakawa K, Mitsuhashi N, Saito Y, et al. Limited field irradiation for medically inoperable patients with peripheral stage I non-small cell lung cancer. Lung Cancer. 1999;26:137–142
  6. Kaskowitz L, Graham MV, Emami B, Halverson KJ, Rush C. Radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1993;27:517–523
  7. Noordijk EM, vd Poest Clement E, Hermans J, Wever AM, Leer JW. Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. Radiother Oncol. 1988;13:83–89
  8. Rosenthal SA, Curran WJ, Herbert SH, et al. Clinical stage II non-small cell lung cancer treated with radiation therapy alone (The significance of clinically staged ipsilateral hilar adenopathy (N1 disease)). Cancer. 1992;70:2410–2417
  9. Sandler HM, Curran WJ, Turrisi AT. The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1990;19:9–13
  10. Zhang HX, Yin WB, Zhang LJ, et al. Curative radiotherapy of early operable non-small cell lung cancer. Radiother Oncol. 1989;14:89–94
  11. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87:198–205
  12. Pigott KH, Saunders MI. The long-term outcome after radical radiotherapy for advanced localized non-small cell carcinoma of the lung. Clin Oncol (R Coll Radiol). 1993;5:350–354
  13. Slotman BJ, Antonisse IE, Njo KH. Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer. Radiother Oncol. 1996;41:41–44
  14. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45:323–329
  15. Marks LB, Munley MT, Bentel GC, et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys. 1997;39:563–570
  16. Martel MK, Ten Haken RK, Hazuka MB, Turrisi AT, Fraass BA, Lichter AS. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys. 1994;28:575–581
  17. Graham MV, Purdy JA, Harms W, Bosch W, Wasserman TH, Perez CA. Survival and prognostic factors of non-small cell lung cancer (NSCLC) patients treated with definitive three-dimensional (3D) radiation therapy. Int J Radiat Oncol Biol Phys. 1998;42:83–84
  18. Robertson JM, Ten Haken RK, Hazuka MB, et al. Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1079–1085
  19. Martel MK, Ten Haken RK, Hazuka MB, et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer. 1999;24:31–37
  20. Armstrong JG, Burman C, Leibel S, et al. Three-dimensional conformal radiation therapy may improve the therapeutic ratio of high dose radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys. 1993;26:685–689
  21. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol. 2001;19:127–136
  22. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:318–328
  23. Rosenzweig KE, Fox JL, Yorke E, et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer. 2005;103:2118–2127
  24. Koutaissoff S, Wellmann D, Coucke P, Ozsahin M, Pampallona S, Mirimanoff RO. Hyperfractionated accelerated radiotherapy (HART) for inoperable, nonmetastatic non-small cell lung carcinoma of the lung (NSCLC): results of a phase II study for patients ineligible for combination radiochemotherapy. Int J Radiat Oncol Biol Phys. 1999;45:1151–1156
  25. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63:1010–1015
  26. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101:1623–1631
  27. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940–945
  28. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer. 1994;10(suppl):S239–S244
  29. Mattson K, Holsti LR, Holsti P, et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol. 1988;24:477–482
  30. Trovo MG, Zanelli GD, Minatel E, Franchin G, Gobitti C. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1992;24:573–574
  31. Wolf M, Hans K, Becker H, et al. Radiotherapy alone versus chemotherapy with ifosfamide/vindesine followed by radiotherapy in unresectable locally advanced non-small cell lung cancer. Semin Oncol. 1994;21:42–47
  32. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88:1210–1215
  33. Sause W, Kolesar P, Taylor SI, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117:358–364
  34. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin (MIC) in non-small cell lung cancer (NSCLC): results from a randomized trial in patients with localized, inoperable disease [abstract]. Lung Cancer. 1997;18:5–10
  35. Kubota K, Furuse K, Kawahara M, et al. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol. 1994;12:1547–1552
  36. Simpson JR, Francis ME, Perez-Tamayo R, Marks RD, Rao DV. Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial. Int J Radiat Oncol Biol Phys. 1985;11:751–758
  37. Armstrong BA, Perez CA, Simpson JR, Hederman MA. Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys. 1987;13:531–539
  38. Macbeth FR, Bolger JJ, Hopwood P, et al. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status (Medical Research Council Lung Cancer Working Party). Clin Oncol (R Coll Radiol). 1996;8:167–175
  39. Bezjak A, Dixon P, Brundage M, et al. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys. 2002;54:719–728
  40. Pirtoli L, Bindi M, Bellezza A, Pepi F, Tucci E. Unfavorable experience with hypofractionated radiotherapy in unresectable lung cancer. Tumori. 1992;78:305–310
  41. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by Its Lung Cancer Working Party. Br J Cancer. 1991;63:265–270
  42. Collins TM, Ash DV, Close HJ, Thorogood J. An evaluation of the palliative role of radiotherapy in inoperable carcinoma of the bronchus. Clin Radiol. 1988;39:284–286
  43. Teo P, Tai TH, Choy D, Tsui KH. A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1988;14:867–871
  44. Carroll M, Morgan SA, Yarnold JR, Hill JM, Wright NM. Prospective evaluation of a watch policy in patients with inoperable non-small cell lung cancer. Eur J Cancer Clin Oncol. 1986;22:1353–1356
  45. Zajac AJ, Kohn ML, Heiser D, Peters JW. High-dose-rate intraluminal brachytherapy in the treatment of endobronchial malignancy (Work in progress). Radiology. 1993;187:571–575
  46. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899–909
  47. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?. J Clin Oncol. 1993;11:1866–1872
  48. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer (Results of a meta-analysis of the literature). Chest. 1994;106:861–865
  49. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 1993;342:19–21
  50. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999;17:3188–3194
  51. Socinski MA, Morris DE, Masters GA, Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest. 2003;123:226S–243S
  52. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 2000;27:145–157
  53. Fossella FV, DeVore R, Kerr RN, et al. TAX 320 Non-Small Cell Lung Cancer Study Group Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000;18:2354–2362
  54. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000;92:1074–1080
  55. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000;18:623–631
  56. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103
  57. Douillard JY, Giaccone G, Horai T, et al. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 (“Iressa”) (IDEAL 1). Proc Am Soc Clin Oncol. 2002;21:299a
  58. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–2191
  59. Natale RR, Skarin AT, Maddox AM, et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 (“Iressa”) (IDEAL 2). Proc Am Soc Clin Oncol. 2002;21:292a

PII: S1546-1440(08)00553-X

doi: 10.1016/j.jacr.2008.11.001

Journal of the American College of Radiology
Volume 6, Issue 2 , Pages 85-95 , February 2009

Article Tools